MENLO PARK, Calif. — July 18, 2006 — ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, said today that Bernelle H. Saperstein has joined the company as Vice President, Manufacturing Operations, a new position. Ms. Saperstein comes to ForteBio from BD-Immunocytometry Systems, where she led a large team responsible for manufacturing and testing reagents for cell analysis.
“Bernelle is an extremely knowledgeable operations executive with manufacturing and materials experience in analytical and diagnostic systems and chemical and pharmaceutical production,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. “We wanted an experienced executive to oversee increasing manufacturing capacity at both our Menlo Park facility and our wholly owned subsidiary in Shanghai, China, in order to meet our expanding shipment requirements. I am delighted to have Bernelle's expertise on our management team.”
Ms. Saperstein's broad-based expertise encompasses all aspects of operations, including planning, inventory and expense control, productivity improvement, quality system implementation and maintenance, regulatory compliance, site management and HR/labor relations. She joined ForteBio in July 2006 from BD-Immunocytometry Systems, where she was Director, Reagent Operations. Previously, she was Vice President, Operations at First Medical, a subsidiary of Sigma Diagnostics. Earlier, she spent more than a decade at Roche Diagnostics where she held a number of management positions with increasing responsibilities, lastly as General Manager. Ms. Saperstein began her career at Merck, where for nearly 20 years she worked first at Merck Research Laboratories and later at the company's Calgon Corporation subsidiary. She received her BS in chemical engineering from Virginia Tech.
About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.
Contact Information :
President & Chief Executive
(650) 322-1360 ext. 111